# A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations

> **NCT06370351** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sensorion** · enrollment: 12 (estimated)

## Conditions studied

- OTOF Gene Mutation
- DFNB9
- Congenital Deafness
- Hearing Disorders
- Ear Diseases
- Otorhinolaryngologic Diseases
- Deafness
- Hearing Loss, Sensorineural

## Interventions

- **COMBINATION_PRODUCT:** SENS-501 administration

## Key facts

- **NCT ID:** NCT06370351
- **Lead sponsor:** Sensorion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-21
- **Primary completion:** 2027-07
- **Final completion:** 2031-07
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06370351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06370351, "A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06370351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*